Program and book of abstracts 1st conference

1 st Conference of European Academy for Molecular Hydrogen Research in Biomedicine “Hydrogen for Biomedicine“

Cinquin Philippe

Mathematics and Medical Doctor, is Professor of Digital Public Health in Grenoble at Univ. Grenoble Alps (UGA) and Grenoble University Hospital (CHUGA). He is the former head of TIMC (UGA & CNRS), and belongs to Centre for Clinical Investigation (INSERM& CHUGA). He pioneered Computer-Assisted Medical Interventions. He is co-author of 146 papers and 43 patents. He focused on the design of implantablemedical devices capable to scavenge energy, and recently on therapeutic applications of hydrogen. He received theMuller Award for excellence in computer-assisted orthopedic surgery, the CNRS Silver and Innovation Awards, and was finalist for the European Inventor Award for a Glucose BioFuel Cell capable to power implanted medical devices. He holds “Deep Care” (a research chair of Grenoble Multidisciplinary Institute of Artificial Intelligence). COVIDROGEN: EXPLORATION IN TWO CLINICAL TRIALS OF THE CLINICAL INTEREST OF HYDROGEN INHALATION AND OF HYDROGEN-RICHWATER INGESTION FOR COVID-19 AMBULATORY OR HOSPITALIZED PATIENTS J. P. Alcaraz 1 , M. Barbado 2 , J. L. Bosson 1 , 2 , F. Boucher 1 , J. P. Brion 3 , P. Cinquin 1,2, B. Degano 4 , C. Eychenne 1 , J. Giai 1,2, C. Ihl 1 , Y. Gaboreau 1 , A. Lefaivre 1 , M. Margotton 3 , A. Milovančev 5 , A. Moreau-Gaudry 1,2 , S. Ostojic 5 , A. Paris 2 , P. Pavèse 3 , C. Rolland 1 , M. Roustit 2 , S. Silvent 1,2, BACKGROUND: Hydrogen-Therapy was recommended very early by Chinese recommendations for Covid patients. Several biochemical pathways by which molecular hydrogen (H2) could prevent the cytokine storm of COVID have been described. OBJECTIVES: demonstrate that: i) early ingestion of Hydrogen-Rich Water (HRW) in mild ambulatory patients could limit complications of COVID; ii) H2 inhalation can safely be proposed to moderate Covid hospitalized patients. METHODS: HydroCovid is a randomized, triple-blind, multicentric and international clinical trial. Included patients are mild ambulatory patients starting Covid, aged 18 or more, with at least one risk factor. Patients ingested twice a day 250 mL of HRW (with tablets containing 80 mg of reduced Mg, donated by DrinkHRW - Canada) or placebo, for 21 days, immediately after diagnosis. Composite Primary Endpoint includes symptom worsening (dyspnea and fatigue), oxygen use, hospitalization and death occurring within 12 to 14 days of inclusion. Patient follow-up is planned for 12 months, to assess benefit of HRW in long Covid. H2-COVID is a phase 1 clinical trial. Covid patients inhaling S. Tanguy 1 , H. Terrisse 1 , S. Touati 2,3, C. Vermorel 1 1 TIMC (Univ. Grenoble Alpes, CNRS, France), 2 CIC1406 (Grenoble Alpes University Hospital, INSERM, France), 3 Service de Maladies Infectieuses (CHU Grenoble Alpes, France), 4 Service de Pneumologie (CHU Grenoble Alpes, France), 5 Faculty of Medicine (University of Novi Sad, Serbia.

30